Long-term outcomes of transcutaneous retrobulbar amphotericin B in COVID-19-associated mucormycosis

PURPOSE: To describe the long-term outcomes of transcutaneous retrobulbar amphotericin B (TRAMB) in COVID-19-associated mucormycosis. METHODS: In total, 18 cases of COVID-19-associated mucormycosis were reviewed. In addition to the recommended treatment protocol, all patients were to be given 3.5 mg...

Descripción completa

Detalles Bibliográficos
Autores principales: Rizvi, Syed Wajahat A, Khan, Shagil, Shahbaz, Mohammad, Gounder, M Srinivasan, Saif, Mohd, Khalid, Saifullah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228905/
https://www.ncbi.nlm.nih.gov/pubmed/36727338
http://dx.doi.org/10.4103/ijo.IJO_1382_22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228905/
https://www.ncbi.nlm.nih.gov/pubmed/36727338
http://dx.doi.org/10.4103/ijo.IJO_1382_22

Ejemplares similares